Reich K - Search Results

1

Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial.

Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, Harfst E, Guettner A, Papavassilis C; CAIN457A2211 study group. Paul C, et al. Among authors: reich k. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1670-5. doi: 10.1111/jdv.12359. Epub 2014 Jan 7. J Eur Acad Dermatol Venereol. 2014. PMID: 24393602 Clinical Trial.

2

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Reich K, et al. Br J Dermatol. 2006 Jun;154(6):1161-8. doi: 10.1111/j.1365-2133.2006.07237.x. Br J Dermatol. 2006. PMID: 16704649 Clinical Trial.

3

[Therapy of psoriasis vulgaris with efalizumab].

Mrowietz U, Barth J, Boehncke WH, Reich K, Rosenbach T, Streit V, Wozel G. Mrowietz U, et al. Among authors: reich k. J Dtsch Dermatol Ges. 2006 Jun;4(6):511-2. doi: 10.1111/j.1610-0387.2006.05885.x. J Dtsch Dermatol Ges. 2006. PMID: 16734844 German. No abstract available.

4

Treatment goals in psoriasis.

Reich K, Mrowietz U. Reich K, et al. J Dtsch Dermatol Ges. 2007 Jul;5(7):566-74. doi: 10.1111/j.1610-0387.2007.06343.x. J Dtsch Dermatol Ges. 2007. PMID: 17610606 Review. English, German.

5

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE. Reich K, et al. Eur J Dermatol. 2007 Sep-Oct;17(5):381-6. doi: 10.1684/ejd.2007.0234. Epub 2007 Aug 2. Eur J Dermatol. 2007. PMID: 17673380 Clinical Trial.

6

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.

Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Rich P, et al. Among authors: reich k. J Am Acad Dermatol. 2008 Feb;58(2):224-31. doi: 10.1016/j.jaad.2007.07.042. Epub 2007 Dec 20. J Am Acad Dermatol. 2008. PMID: 18083272 Clinical Trial.

7

Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.

Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu MC, Guzzo C, Diels J, Gelfand JM. Menter A, et al. Among authors: reich k. J Drugs Dermatol. 2008 Dec;7(12):1137-46. J Drugs Dermatol. 2008. PMID: 19137767

8

Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE).

Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Reich K, et al. J Dtsch Dermatol Ges. 2009 Jul;7(7):603-11. doi: 10.1111/j.1610-0387.2009.07120.x. Epub 2009 May 4. J Dtsch Dermatol Ges. 2009. PMID: 19459898 English, German.

9

[15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris].

Mrowietz U, Rostami-Yazdi M, Neureither M, Reich K. Mrowietz U, et al. Among authors: reich k. J Dtsch Dermatol Ges. 2009 Apr;7 Suppl 2:S3-16. doi: 10.1111/j.1610-0387.2009.07059.x. J Dtsch Dermatol Ges. 2009. PMID: 19522921 Review. German. No abstract available.

10

Psoriasis--new insights into pathogenesis and treatment.

Mrowietz U, Reich K. Mrowietz U, et al. Among authors: reich k. Dtsch Arztebl Int. 2009 Jan;106(1-2):11-8, quiz 19. doi: 10.3238/arztebl.2009.0011. Epub 2009 Jan 5. Dtsch Arztebl Int. 2009. PMID: 19564982 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

582 results

Search Page